Cambridge Investment Research Advisors Inc. acquired a new stake in Bausch Health Companies Inc (NYSE:BHC) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 12,804 shares of the company’s stock, valued at approximately $329,000.
Other institutional investors have also made changes to their positions in the company. NEXT Financial Group Inc purchased a new stake in shares of Bausch Health Companies in the 3rd quarter worth $101,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Bausch Health Companies in the 3rd quarter worth $106,000. Polaris Greystone Financial Group LLC purchased a new stake in shares of Bausch Health Companies in the 3rd quarter worth $107,000. Quadrant Capital Group LLC purchased a new stake in shares of Bausch Health Companies in the 3rd quarter worth $118,000. Finally, Bedel Financial Consulting Inc. purchased a new stake in shares of Bausch Health Companies in the 3rd quarter worth $129,000. 42.74% of the stock is currently owned by institutional investors.
Shares of NYSE BHC opened at $24.35 on Friday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.14 and a quick ratio of 0.91. The firm has a market cap of $8.30 billion, a P/E ratio of 6.36, a P/E/G ratio of 0.31 and a beta of -0.28. Bausch Health Companies Inc has a 1-year low of $14.44 and a 1-year high of $28.45.
Several equities research analysts have weighed in on the company. Mizuho upped their target price on Bausch Health Companies from $35.00 to $38.00 and gave the stock a “buy” rating in a report on Friday. BMO Capital Markets reiterated a “hold” rating and issued a $26.00 target price on shares of Bausch Health Companies in a report on Tuesday, November 13th. ValuEngine cut Bausch Health Companies from a “hold” rating to a “sell” rating in a report on Monday, November 12th. TD Securities upped their target price on Bausch Health Companies from $24.00 to $28.00 and gave the stock a “hold” rating in a report on Wednesday, November 7th. Finally, Royal Bank of Canada upped their target price on Bausch Health Companies from $30.00 to $31.00 and gave the stock a “hold” rating in a report on Wednesday, November 7th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $28.18.
In related news, CFO Paul Herendeen acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The stock was purchased at an average cost of $22.61 per share, for a total transaction of $226,100.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Schutter Richard U. De acquired 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The shares were bought at an average price of $23.96 per share, with a total value of $2,995,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 165,000 shares of company stock valued at $3,890,700 over the last 90 days. 11.54% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Cambridge Investment Research Advisors Inc. Takes $329,000 Position in Bausch Health Companies Inc (BHC)” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.com-unik.info/2018/12/02/cambridge-investment-research-advisors-inc-takes-329000-position-in-bausch-health-companies-inc-bhc.html.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Featured Story: Why do corrections happen?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.